News & Events
Published On: 3/13/2020
TARGET PharmaSolutions Launches Real-World Asthma Study
DURHAM, N.C., March 13, 2020 /PRNewswire/ -- TARGET PharmaSolutions Inc., a real-world evidence clinical data company, announced today the launch of its seventh observational cohort study, TARGET-ASTHMA.
"TARGET-ASTHMA will capture important data on patients with asthma in the real world," said Steering Committee Chair, Michael Wechsler, MD, Professor of Medicine and Director of the National Jewish Health Cohen Family Asthma Institute. "This will not only aid in mapping the natural history of asthma but will also provide insights into the impact of different treatment paradigms on patient populations over time and collect real-world data as new agents are proceeding to market."
TARGET-ASTHMA is a longitudinal study of participants being treated for asthma, and will capture additional respiratory diseases in the future, extending 3-years retrospectively prior to patient consent and 10-years prospectively. Structured and unstructured medical record data is received from community and academic sites to build the database, including patient-reported outcome measures and biorepository samples. Partners utilize the real-world data throughout pharmaceutical development and commercialization processes to inform optimal treatment approaches and potential solutions.
"In working with partners and investigative sites, there has been significant interest in a reliable, longitudinal view of patients with respiratory complications, like asthma, to better understand the challenges of this chronic disease," said TARGET PharmaSolutions CEO, Neal Bibeau. "We are pleased to announce the launch of TARGET-ASTHMA and the enrollment of our first patient. We look forward to working with Dr. Wechsler and other key leaders in this area."
The company launched its first real-world disease community in nonalcoholic steatohepatitis, TARGET-NASH, in 2016, which is in its fourth year of data collection. Other ongoing TARGET studies include hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), and chronic hepatitis B (HBV).
The TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis about its natural history, current treatment paradigms, and patient outcomes. Stakeholders include key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who provide direction for the study aims and structure.
About TARGET PharmaSolutions
TARGET is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners more efficient ways to generate data in real-world settings. For more information, visit www.targetpharmasolutions.com.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
05/07/2020Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
04/14/2020TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
03/17/2020TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
03/13/2020TARGET PharmaSolutions Launches Real-World Asthma Study